Albeit with their impressive efficacies in clinic, hematological toxicities such as anemia, neutropenia, and thrombocytopenia are common adverse events (AEs) during first-generation PARP inhibitors treatment.137 These safety risks lead to dose discontinuation and reduce combination possibilities with chemotherapy or other kinds of therapies. The gene discussed is PARP1; the disease is Decreased total neutrophil count.